Construction method of inducible mouse cystic nephropathy model

By inserting LoxP sequences at both ends of the mouse GGPS1 gene and using Cdh16-CreERT2 enzyme, combined with tamoxifen induction, an inducible mouse cystic kidney disease model was constructed, solving the problem that the existing model could not effectively simulate the pathological process of cystic kidney disease. Problem, achieving high representation and stability of the model, suitable for research and drug development.

CN119054651APending Publication Date: 2024-12-03SIR RUN RUN HOSPITAL NANJING MEDICAL UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411083006.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing animal models cannot effectively respond to the severity of cystic kidney disease, and there is a lack of research tools that can simulate the pathological processes of cystic kidney disease in humans.

Method used

By inserting LoxP sequences at both ends of the mouse GGPS1 gene, combining the use of Cdh16-CreERT2 enzyme and tamoxifen, a specific drug induced knockout of the GGPS1 gene in renal tubular epithelial cells, and constructing an inducible mouse cystic kidney disease model.

Benefits of technology

The constructed model showed multiple cystic dilated renal tubules in the third week after drug induction, and renal cysts began to form in the seventh week, with increased serum creatinine and urea nitrogen levels, which are highly representative and can simulate the pathology of human cystic kidney disease. Process, suitable for studying disease mechanisms and drug development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119054651A_ABST
    Figure CN119054651A_ABST
Patent Text Reader

Abstract

The invention provides a construction method of an inducible mouse cystic nephropathy model, which comprises the following steps: inserting an LoxP sequence into two ends of a mouse GGPS1 gene to obtain an LoxP-flox-GGPS1 mouse, introducing CreERT2 recombinase, and under the induction of tamoxifen, specifically knocking out the GGPS1 gene to obtain the model. A plurality of cystic dilated renal tubules appear in kidney tissues of the mouse model in the third week after drug induction, renal cysts start to be formed in the seventh week, meanwhile, the conditions of serum creatinine and urea nitrogen increase occur, the conditions conform to the symptoms and the pathological process of the human cystic nephropathy, and the mouse model can be used for researching the occurrence and development mechanism of the cystic nephropathy and has a good application prospect. The invention also relates to development of drugs for treating the diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biomedicine, and in particular to a method for constructing an induced mouse cystic kidney disease model. Background Art

[0002] Cystic kidney disease refers to a type of disease in which single or multiple benign cysts appear in the kidneys. It can occur at all ages, including infancy, childhood and adulthood. These cysts contain fluid and can occur in the renal cortex, medulla and corticomedullary tissues. Depending on whether the cystic kidney disease has a hereditary cause, it can be divided into two categories: hereditary cystic kidney disease and non-hereditary cystic kidney disease. The most common hereditary cystic kidney diseases are autosomal dominant polycystic kidney disease and autosomal recessive polycystic kidney disease, while simple renal cysts are the most common non-hereditary cystic kidney disease. Cystic kidney disease can cause many complications, such as intracystic infection, cyst rupture and bleeding, cyst malignancy, renal parenchyma or collecting system compression, chronic renal insufficiency, end-stage renal failure, hypertension, urinary tract infection, kidney stones, renal malignant tumors and extrarenal manifestations. These complications seriously affect the quality of life of patients with cystic kidney disease.

[0003] Due to the medical ethics restrictions on human experiments, animal models have become an important tool for studying the occurrence and development of polycystic kidney disease and exploring preventive measures. However, there is currently no animal model that can well reflect the severity of cystic kidney disease. The mouse genome is more than 90% similar to the human genome, and its kidney growth and development is similar to that of humans. Therefore, the establishment of this animal model can provide a new path for the disease characteristics, pathogenesis, disease prognosis, drug development and screening of cystic kidney disease. Summary of the invention

[0004] The purpose of the present invention is to provide a method for constructing an inducible mouse cystic kidney disease model, so as to develop an inducible mouse cystic kidney disease model for studying the occurrence and development mechanism of cystic kidney disease and for developing drugs for treating the disease.

[0005] To achieve the above object, the present invention provides the following technical solutions:

[0006] In a first aspect, the present invention discloses a method for constructing an inducible mouse cystic kidney disease model, the method comprising the following steps:

[0007] S1. Select mice, insert LoxP sequences at both ends of their GGPS1 gene, screen for stable integration strains, and obtain LoxP-flox-GGPS1 mice;

[0008] S2, mating the LoxP-flox-GGPS1 mouse with a tool mouse carrying the Cdh16-CreERT2 enzyme and backcrossing and purification to obtain mice with purified LoxP-flox-GGPS1 and Cdh16-CreERT2 genes in renal tubular epithelial cells;

[0009] S3. Mice carrying both LoxP-flox-GGPS1 and Cdh16-CreERT2 genes were injected with tamoxifen after birth to obtain mice with specific drug-induced knockout of the GGPS1 gene in tubular epithelial cells.

[0010] Preferably, the selected mice are C57BL / 6 background mice of specific pathogen-free animal grade.

[0011] Preferably, tamoxifen is injected on the 10th day after birth, with continuous intraperitoneal injection for 5 days, and the injection dose is 40 mg / kg.

[0012] Preferably, the method further comprises the steps of:

[0013] S4. Verify whether the GGPS1 gene knockout mouse obtained in step S3 is an inducible mouse cystic kidney disease model.

[0014] The verification method is selected from one or more of the following:

[0015] (1) Genotype identification: The genotype of the inducible mouse cystic kidney disease model was identified by conventional PCR technology and verified by western blotting at the protein level;

[0016] (2) Testing the biochemical indicators of serum creatinine and blood urea levels in the GGPS1 knockout mice;

[0017] (3) The renal pathological changes of GGPS1 gene knockout mice were examined by eosin staining.

[0018] In a second aspect, the present invention also provides an induced mouse cystic kidney disease model constructed using the above construction method.

[0019] Compared with the prior art, the present invention has the following beneficial effects: the present invention provides a method for constructing an inducible mouse cystic kidney disease model, the method comprising inserting LoxP sequences into both ends of the mouse GGPS1 gene to mark and effectively knock out the GGPS1 gene. The present invention induces the knockout of tubular epithelial cell GGPS1 by specific drugs to construct a cystic kidney disease mouse model, wherein multiple cystic dilated tubules appear in the renal tissue of the mouse model in the third week after drug induction, and renal cysts begin to form in the seventh week, and at the same time, blood creatinine and urea nitrogen increase, which is consistent with the symptoms and pathological process of human cystic kidney disease, and can be used to study the occurrence and development mechanism of cystic kidney disease, as well as the development of drugs for treating the disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Construction of a flowchart for drug-induced tubule-specific knockout of GGPS1 mice;

[0021] Figure 2 This is a gel photo of the mouse genotype verified using common PCR amplification technology and nucleic acid gel electrophoresis;

[0022] Figure 3 The figure is a comparison of the expression of GGPS1 protein in kidney tissues of control and model mice by western blotting;

[0023] Figure 4 This is the ultrasound examination image of the kidneys of the model mice at week 7 after drug induction.

[0024] Figure 5 This is the appearance of the kidneys of model mice at week 11 after drug induction.

[0025] Figure 6 These are the eosin-stained pathological images of the kidneys of model mice at 3, 5, and 11 weeks after drug induction.

[0026] Figure 7 This is a statistical comparison chart of serum urea nitrogen index of renal function in model mice at 1, 3, 5, and 11 weeks after drug induction.

[0027] Figure 8 This is a statistical comparison chart of serum creatinine indicators of renal function in model mice at 1, 3, 5, and 11 weeks after drug induction. DETAILED DESCRIPTION

[0028] GGPS1 is a pivot enzyme in the mevalonate pathway, which can catalyze the synthesis of geranylgeranyl pyrophosphate from farnesyl pyrophosphate. The inventors' research shows that GGPS1 is specifically expressed in mouse and human renal tubular epithelial cells and is related to kidney development. GGPS1 expression is significantly reduced in renal tissue of patients with cystic kidney disease, which lays a theoretical foundation for constructing a cystic kidney disease mouse model with renal tubular epithelial-specific drug-induced knockout of the GGPS1 gene.

[0029] Based on the theoretical foundation found above, the present invention provides a method for constructing an inducible mouse cystic kidney disease model by knocking out the GGPS1 gene of mouse renal tubular epithelial cells through specific drug induction, thereby filling the gap in the prior art. The mouse model has multiple cystic dilated tubules in its renal tissue in the third week after drug induction, and renal cysts begin to form in the seventh week, and blood creatinine and urea nitrogen increase at the same time, which is consistent with the symptoms and pathological process of human cystic kidney disease, and can be used to study the occurrence and development mechanism of cystic kidney disease, as well as the development of drugs for treating the disease.

[0030] In an exemplary embodiment, the purpose of the present invention can be achieved by the following technical solutions:

[0031] The present invention inserts LoxP sequences into both ends of the mouse GGPS1 gene to mark and effectively knock out the GGPS1 gene, thereby obtaining mice with LoxP sequences inserted into both ends of the GGPS1 gene, which are named LoxP-flox-GGPS1 mice, i.e., GGPS1 fl / fl When the mouse is introduced with CreERT2 recombinase and induced by tamoxifen, CreERT2 recombinase recognizes the LoxP site and removes the sequence between the LoxP sites, thereby achieving the purpose of specifically knocking out the GGPS1 gene at a specific time and in specific cells.

[0032] In a preferred embodiment, GGPS1 fl / fl The mice were mated with tool mice carrying the Cdh16-CreERT2 enzyme and backcrossed to purify the neonatal polycystic kidney model, namely GGPS1 fl / fl :Cdh16CreERT2 mice.

[0033] In a preferred exemplary embodiment, the specific method comprises the following steps:

[0034] 1) Select mice with a C57BL / 6 background free of specific pathogens, insert LoxP sequences at both ends of the GGPS1 gene, and integrate the target gene with LoxP fragments into the original genome to obtain LoxP-flox-GGPS1 mice, i.e. GGPS1 fl / fl Mice;

[0035] 2) The GGPS1 fl / fl The mice were mated with tool mice carrying the Cdh16-CreERT2 enzyme and backcrossed for purification, thereby obtaining mice with both the purified LoxP-flox-GGPS1 and Cdh16-CreERT2 genes in the renal tubular epithelial cells;

[0036] 3) The genotype of the mouse obtained in step 2) is the purified LoxP-flox-GGPS1 and carries the Cdh16-CreERT2 gene, i.e., GGPS1 fl / fl : Cdh16CreERT2 mice were intraperitoneally injected with tamoxifen for 5 consecutive days starting from the 10th day after birth, with an injection dose of 40 mg / kg, to obtain mice with specific drug-induced knockout of the GGPS1 gene in renal tubular epithelial cells;

[0037] 4) Verify that the mice with the genotype obtained in step 3) are the purified LoxP-flox-GGPS1 and Cdh16-CreERT2 genes and intraperitoneally injected with tamoxifen are the induced mouse cystic kidney disease model, i.e., GGPS1 fl / fl :Cdh16CreERT2 mice.

[0038] In the verification step of the present invention, the genotype of the mouse is generally determined by detecting the mouse tail, and whether the GGPS1 gene is a wild type (neither of the two paired DNA chains has a flox sequence inserted at both ends of its GGPS1 gene), a heterozygous type (only one of the two paired DNA chains has a flox sequence inserted at both ends of its GGPS1 gene), or a fl / fl type (both of the two paired DNA chains have a flox sequence inserted at both ends of its GGPS1 gene).

[0039] In a preferred exemplary embodiment, the method for verifying whether the mouse model obtained in step 3) is successfully constructed is selected from one or more of the following:

[0040] (1) Genotype identification: The genotype of the inducible mouse cystic kidney disease model was identified by conventional PCR technology and verified by western blotting at the protein level;

[0041] (2) testing the biochemical indicators of blood creatinine and blood urea levels of the obtained mice;

[0042] (3) The renal pathological changes of mice were examined by eosin staining.

[0043] The method for constructing an inducible mouse cystic kidney disease model of the present invention is to construct the inducible mouse cystic kidney disease model by knocking out the GGPS1 gene of mouse renal tubular epithelial cells by induction with specific drugs.

[0044] The method of the present invention has the following benefits:

[0045] 1. The present invention uses a mouse model, whose genome is highly similar to that of humans, and can simulate the natural state in the human body to conduct basic experiments, reducing the necessity of conducting experiments on humans and the damage to the human body;

[0046] 2. The inducible mouse cystic kidney disease model constructed by the present invention has a stable phenotype after successful construction, and can stably show the cystic kidney disease phenotype in the breeding environment of different regions, with high repeatability;

[0047] 3. The mouse model showed multiple cystic dilated tubules in the kidney tissue in the third week after drug induction, and renal cysts began to form in the seventh week. At the same time, blood creatinine and urea nitrogen increased, which was consistent with the symptoms and pathological process of human cystic kidney disease and was quite representative.

[0048] 4. It can be used to study the occurrence and development mechanism of polycystic kidney disease in adults and infants, as well as the development of drugs to treat the disease.

[0049] In general, the present invention induces conditional knockout of the GGPS1 gene in renal tubular epithelial cells through drug-induced, and the constructed inducible mouse cystic kidney model is consistent with the symptoms and pathological process of human cystic kidney disease, and can be used to study the occurrence and development mechanism of cystic kidney disease, as well as for the development of drugs to treat the disease.

[0050] The following will be combined with the specific embodiments of the present invention and the accompanying drawings to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0051] In the description of the present invention, it should be noted that the terms "upper", "lower", "inner", "outer", "front end", "rear end", "two ends", "one end", "the other end" and the like indicating the orientation or positional relationship are only for the convenience of describing the present invention and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, be constructed and operate in a specific orientation, and therefore cannot be understood as limiting the present invention. In addition, the terms "first" and "second" are only used for descriptive purposes and cannot be understood as indicating or implying relative importance.

[0052] In the description of the present invention, it should be noted that, unless otherwise clearly specified and limited, the terms "installed", "provided with", "connected", etc. should be understood in a broad sense. For example, "connected" can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection, or it can be indirectly connected through an intermediate medium, or it can be the internal communication of two components. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.

[0053] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.

[0054] The terms in this invention are explained as follows:

[0055] 1. C57BL / 6: It is a common inbred strain of laboratory mice. It is widely used as a transgenic mouse in genetic experiments to simulate human gene defect diseases. Because it can be used as a congenic strain, is easy to breed and has a strong physique, it is the most widely used and best-selling mouse strain. Although the present invention uses it as an example, technicians in the industry should understand that there are other varieties of mice that can also be used to construct models, so the use of this variety in the embodiment should not limit the scope of protection of the present invention.

[0056] 2. LoxP sequence: It is a 34bp sequence located in the P1 bacteriophage and is also a mature tool sequence in the existing technology.

[0057] 3. Flox mice: a conditional knockout mouse, which refers to mice containing a pair of LoxP sequences in the target gene. fl / fl represents flox / flox, that is, both paired DNA chains have LoxP sequences inserted at both ends of their GGPS1 genes. fl / - represents flox / -, that is, only one of the two DNA chains has LoxP sequences inserted at both ends of its GGPS1 gene, and the other DNA chain has no LoxP sequences inserted at both ends of its GGPS1 gene.

[0058] 4. CreERT2-LoxP recombinase system: includes CreERT2 recombinase and LoxP sequence. CreERT2 recombinase is a type of protein that contains a fusion expression of a mutant of the ligand binding region of the estrogen receptor and the Cre recombinase. CreERT2 is inactive in the cytoplasm without tamoxifen induction; when tamoxifen is induced, the estrogen analogue, a metabolite of tamoxifen, binds to the mutant of the ligand binding region of the estrogen receptor, allowing CreERT2 to enter the cell nucleus to exert Cre recombinase activity, recognize specific DNA sequences, namely LoxP sites, and cause gene recombination between the two LoxP sites.

[0059] 5. Cdh16 gene: This gene is specifically expressed in renal tubular epithelial cells.

[0060] 6. Cdh16-CreERT2 gene mouse: It is a tool mouse carrying Cdh16-CreERT2 enzyme. It is a mouse that contains both Cdh16 gene and CreERT2 recombinase. This tool mouse can be purchased directly, for example, from Jiangsu Jicui Pharmaceutical Kang Biotechnology Co., Ltd.

[0061] 7. GGPS1 fl / fl Mouse, GGPS1 fl / - :Cdh16CreERT2 mice, GGPS1 fl / fl :Cdh16CreERT2 mice:GGPS1 fl / fl The mouse refers to a mouse in which both paired DNA chains have LoxP sequences inserted at both ends of the GGPS1 gene, which does not carry the Cdh16-CreERT2 gene and the GGPS1 gene cannot be knocked out by tamoxifen. fl / - :Cdh16CreERT2 mice refer to mice in which only one of the two DNA chains in the body has LoxP sequences inserted at both ends of the GGPS1 gene, while the other DNA chain has no LoxP sequences inserted at both ends of the GGPS1 gene. They carry the Cdh16-CreERT2 gene, but the GGPS1 gene cannot be knocked out by tamoxifen. GGPS1 fl / fl :Cdh16CreERT2 mice refer to mice in which LoxP sequences are inserted at both ends of the GGPS1 gene in the two paired DNA chains in the body. They carry the Cdh16-Cre gene and the GGPS1 gene can be knocked out by tamoxifen.

[0062] In the method for constructing an inducible mouse cystic kidney disease model of the present invention, step 1) is entrusted to Jiangsu Jicui Yaokang Biotechnology Co., Ltd. to complete, that is, in the embryonic stem cell stage of mice with a C57BL / 6 background at the specific pathogen-free animal level, LoxP sequences are inserted at both ends of the GGPS1 gene, and the target gene with LoxP fragments is integrated into the original genome. The obtained mice are marked as LoxP-flox-GGPS1 mice, i.e., GGPS1 fl / fl The genetic company breeds mice and delivers two parent mice, one male and one female, to the client. The client, i.e., the inventor of the present invention, breeds sufficient numbers of mice with the genotype GGPS1 using these two mice. fl / fl of mice.

[0063] In step 1) of the present invention, LoxP sequences are simply inserted at both ends of the GGPS1 gene, and combined with the subsequent step 2), mice with GGPS1 gene knockout in renal tubular epithelial cells induced by specific drugs are obtained.

[0064] In step 2) of the present invention, LoxP-flox-GGPS1 mice (i.e. GGPS1 fl / fl The mice were mated with commercially available tool mice carrying the Cdh16-CreERT2 enzyme to obtain mice with a heterozygous LoxP-flox-GGPS1 genotype and carrying the Cdh16-CreERT2 gene (i.e., GGPS1 fl / - :Cdh16CreERT2 mice), such as Figure 1 As shown, the obtained GGPS1 fl / - Cdh16CreERT2 mice and GGPS1 fl / fl Mice are backcrossed to obtain the GGPS1 of the present invention fl / fl :Cdh16CreERT2 mice, i.e., inducible mouse cystic kidney disease model mice. In the mice obtained after backcrossing, the mouse GGPS1 gene can be homozygous (GGPS1 fl / fl ) or heterozygous (GGPS1 fl / - ). In addition, the Cdh16-CreERT2 gene may also be positive or negative, that is, carry or not carry the Cdh16-CreERT2 gene.

[0065] The mouse model obtained in the present invention is intraperitoneally injected with tamoxifen for 5 consecutive days starting from the 10th day after birth, with an injection dose of 40 mg / kg, to obtain mice with specific drug-induced knockout of the GGPS1 gene in renal tubular epithelial cells. Renal cyst formation can be observed by color Doppler ultrasonography of the kidneys in the 7th week after drug induction, and pathological manifestations of renal cysts can be observed in all model mice in the 11th week.

[0066] Figure 1 Flowchart for constructing drug-induced tubule-specific knockout mice of GGPS1. Figure 1 As shown in the figure, the GGPS1 delivered by the gene company to the applicant of the present invention is first fl / fl The mice were mated with commercially available tool mice carrying the Cdh16-CreERT2 enzyme to obtain GGPS1 fl / - :Cdh16CreERT2 mice and crossed them with GGPS1 fl / fl The mouse model GGPS1 was obtained by backcrossing fl / - :Cdh16CreERT2 mice.

[0067] Figure 2a shows that in step 3) of the present invention, the genotype of the mouse Cdh16-CreERT2 gene is verified by ordinary PCR amplification technology and nucleic acid gel electrophoresis. The leftmost and rightmost columns are standard reagents divided into several bright bands, which are used to indicate the size of the nucleic acid; among them, the 2nd and 4th columns from the right are mice carrying the Cdh16-CreERT2 gene, and the nucleic acid size is 1716bp; the 2nd column from the left is a blank control; and the mice corresponding to the remaining multiple bands are all mice that do not carry the Cdh16-CreERT2 gene.

[0068] Figure 2 b shows that in step 3) of the present invention, the genotype of the mouse LoxP-flox-GGPS1 gene is verified again by using ordinary PCR amplification technology and nucleic acid gel electrophoresis. The leftmost and rightmost columns are standard reagents divided into several bright bands, which are used to indicate the size of the nucleic acid; the second column from the left is a blank control; the second and third columns from the right are homozygous, that is, LoxP sequences are inserted at both ends of the GGPS1 gene of the two DNA chains, and the nucleic acid size of the two chains is 650 bp; the fourth and fifth columns from the left are heterozygous, that is, LoxP sequences are inserted at both ends of the GGPS1 gene of one of the paired DNA chains, and the nucleic acid size is 650 bp, while the GGPS1 gene of the other nuclear chain has no LoxP sequences inserted at both ends, and the nucleic acid size is 551 bp; the third column from the left is a wild type, and the nucleic acid size of the two chains is 551 bp.

[0069] from Figure 2 It can be seen that the GGPS1 carrying the Cdh16-CreERT2 gene and the homozygous LoxP-flox-GGPS1 gene obtained in the present invention fl / fl : Cdh16CreERT2 mice were intraperitoneally injected with tamoxifen for 5 consecutive days starting from the 10th day after birth, with an injection dose of 40 mg / kg, to obtain mice with specific drug-induced knockout of the GGPS1 gene in renal tubular epithelial cells. Mice with homozygous LoxP-flox-GGPS1 gene but not carrying Cdh16-CreERT2 gene can be used as control mice of the model mice in the present invention.

[0070] Figure 3 The figure is a comparison of the expression levels of GGPS1 protein in the kidney tissues of control and model mice by western blotting.

[0071] in Figure 3 a is for detecting GGPS1 fl / fl Mice and GGPS1 fl / fl : Western blotting of GGPS1 protein expression and internal reference β-actin protein expression in kidney tissue of Cdh16CreERT2 mice. Figure 3 b is GGPS1fl / fl Mice and GGPS1 fl / fl : Statistical diagram of the relative expression of GGPS1 protein and internal reference β-actin protein in the kidney tissue of Cdh16CreERT2 mice, each point in the figure represents a mouse. As can be seen from the figure, the expression of GGPS1 protein in the kidney tissue of the control mice was significantly higher than that of the model mice, and there was a statistical difference between the two, and P < 0.001 (*** represents P < 0.001).

[0072] Figure 4 The ultrasound examination of the kidneys of the model mice at week 7 after drug induction was completed. The left kidney and renal cyst are indicated.

[0073] Figure 5 This is the appearance of the kidneys of model mice at week 11 after drug induction. Figure 5 b is Figure 5 Partial enlargement of a. Figure 5 The arrow in b points to a renal cyst.

[0074] Figure 6 These are the eosin-stained pathological images of the kidneys of model mice at 3, 5, and 11 weeks after drug induction. Figure 6 a and 6b are GGPS1 fl / fl Renal eosin staining pathology of mice 3 weeks after drug induction. Figure 6 c and 6d are GGPS1 fl / fl :Pathological image of kidney eosin staining in Cdh16CreERT2 mice at week 3 after drug induction. Figure 6 e and 6f are GGPS1 fl / fl Renal eosin staining pathology of mice at week 7 after drug induction. Figure 6 g and 6h for GGPS1 fl / fl :Pathological image of kidney eosin staining in Cdh16CreERT2 mice at week 7 after drug induction. Figure 6 i and 6j are GGPS1 fl / fl Renal eosin staining pathology of mice at week 11 after drug induction. Figure 6 k and 6l are GGPS1 fl / fl : Pathological image of kidney eosin staining of Cdh16CreERT2 mice at week 11 after drug induction. Figure 6 As shown, with GGPS1 fl / fl Compared with mice, GGPS1 fl / fl:The kidneys of Cdh16CreERT2 mice showed a large number of tubular cystic dilatations in the third week after drug-induced gene knockout, which gradually worsened in the fifth week. In the 11th week, pathological manifestations of multiple renal cysts were observed in the model mice.

[0075] Figure 7 This is a statistical comparison chart of the serum urea nitrogen index of renal function in model mice at 1, 3, 5, and 11 weeks after drug induction. Figure 7 It can be seen that each data point in the figure represents a mouse. Figure 7 Figure 2 is a schematic diagram for comparing serum urea nitrogen levels. Figure 7 As shown, at 11 weeks after drug-induced gene knockout, the expression of GGPS1 fl / fl Compared with mice, GGPS1 fl / fl :The urea level of Cdh16CreERT2 mice was higher, and the difference was statistically significant, P < 0.01 (* represents P < 0.05, ** represents P < 0.01).

[0076] Figure 8 This is a statistical comparison chart of serum creatinine index of renal function in model mice at 1, 3, 5, and 11 weeks after drug induction. Figure 8 It can be seen that each data point in the figure represents a mouse. Figure 8 This is a schematic diagram of serum creatinine level comparison. Figure 8 As shown, at 11 weeks after drug-induced gene knockout, the expression of GGPS1 fl / fl Compared with mice, GGPS1 fl / fl :The urea level in Cdh16CreERT2 mice was higher, and the difference was statistically significant, P < 0.01 (** represents P < 0.01).

[0077] As can be seen from the above, the present invention constructs an inducible mouse cystic kidney disease model with specific expression, stable phenotype, and the ability to simulate the natural disease state of human cystic kidney disease. The GGPS1 gene in the renal tubular epithelial cells of mice was knocked out by specific drug induction through gene knockout technology, and the construction of the cystic kidney disease mouse model was realized. The kidneys of the mouse model had a large number of tubular cystic dilatations in the third week after drug-induced gene knockout. Renal cysts were observed in mice in the seventh week. In the 11th week, all model mice were observed to have pathological manifestations of renal cysts, and there were abnormal laboratory tests such as increased serum urea nitrogen and serum creatinine, which were consistent with the pathological changes of cystic kidney disease. The disease model has a stable phenotype, symptoms can appear regularly, and the affected parts are specific, which can be used to study the occurrence and development mechanism of cystic kidney disease, as well as the development of drugs for treating the disease.

[0078] The matters not described in detail in the present invention are all known technologies to those skilled in the art.

[0079] Finally, it should be noted that the above specific implementation methods are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified and replaced by equivalents without departing from the spirit and scope of the technical solution of the present invention, which should be included in the scope of the claims of the present invention.

Claims

1. A method for constructing an inducible mouse cystic kidney disease model, characterized in that: The method comprises the following steps: S1. Select mice, insert LoxP sequences at both ends of their GGPS1 gene, screen for stable integration strains, and obtain LoxP-flox-GGPS1 mice; S2, mating the LoxP-flox-GGPS1 mouse with a tool mouse carrying the Cdh16-CreERT2 enzyme and backcrossing and purification to obtain mice with purified LoxP-flox-GGPS1 and Cdh16-CreERT2 genes in renal tubular epithelial cells; S3. Mice carrying both LoxP-flox-GGPS1 and Cdh16-CreERT2 genes were injected with tamoxifen after birth to obtain mice with specific drug-induced knockout of the GGPS1 gene in tubular epithelial cells.

2. The method for constructing an inducible mouse cystic kidney disease model according to claim 1, characterized in that: The mice used were C57BL / 6 mice with specific pathogen-free animal grade.

3. The method for constructing an inducible mouse cystic kidney disease model according to claim 1, characterized in that: Tamoxifen is injected on the 10th day after birth, with a continuous intraperitoneal injection for 5 days, and the injection dose is 40 mg / kg.

4. The method for constructing an inducible mouse cystic kidney disease model according to claim 1, characterized in that: Also includes the steps: S4. Verify whether the GGPS1 gene knockout mouse obtained in step S3 is an inducible mouse cystic kidney disease model.

5. The method for constructing an inducible mouse cystic kidney disease model according to claim 4, characterized in that: The verification method is selected from one or more of the following: (1) Genotype identification: The genotype of the induced mouse cystic kidney disease model was identified by conventional PCR technology and verified by western blotting at the protein level; (2) Testing the biochemical indicators of serum creatinine and blood urea levels in the GGPS1 knockout mice; (3) Renal pathological changes in GGPS1 knockout mice were examined by eosin staining.

6. An inducible mouse cystic kidney disease model, characterized in that: The model is constructed using the method according to any one of claims 1 to 6.

Citation Information

Patent Citations

  • Construction of mouse model capable of realizing Yap1 gene conditional knock out by vascular smooth muscle cells

    CN111909958A

  • Method for constructing polycystic kidney model of newborn mouse

    CN117448385A